RegenETP (DB:NJT) - Aktienkurs, Nachrichten und Analyse

NJT Aktienübersicht

A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.

Über das Unternehmen

NJT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Belohnungen

Risikoanalyse

RegenETP, Inc. Wettbewerber

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Epigenomics

XTRA:ECX

€1.3m

Sangui Biotech International

HMSE:SBH

€419.8k

Paion

DB:PA8K

€214.0k

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for RegenETP
Historical stock prices
Current Share Price	US$0.22
52 Week High	US$0.99
52 Week Low	US$0.20
Beta	0.86
1 Month Change	0%
3 Month Change	10.00%
1 Year Change	-75.56%
3 Year Change	-98.99%
5 Year Change	-99.94%
Change since IPO	-99.99%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	NJT	DE Biotechs	DE Markt
7D	0%	-2.7%	-3.1%
1Y	-75.6%	-24.2%	-0.5%

Preisvolatilität

Is NJT's price volatile compared to industry and market?
NJT volatility
NJT Average Weekly Movement	n/a
Biotechs Industry Average Movement	4.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.5%

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	43	Richard Hague	www.polarityte.com

RegenETP, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von RegenETP im Vergleich zum Marktanteil des Unternehmens?
NJT grundlegende Statistiken
Marktanteil	€436.38k
Gewinn(TTM)	-€7.75m
Umsatz(TTM)	€68.13k

6.4x

Kurs-Umsatz-Verhältnis

-0.1x

Kurs-Gewinn-Verhältnis

Ist NJT zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NJT Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$73.00k
Kosten der Einnahmen	US$125.00k
Bruttogewinn	-US$52.00k
Sonstige Ausgaben	US$8.25m
Umsatz	-US$8.30m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.15
Bruttomarge	-71.23%
Nettogewinnspanne	-11,376.71%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich NJT auf lange Sicht entwickelt?

Historische Performance und Vergleiche

NJT Aktienübersicht

Belohnungen

Risikoanalyse

RegenETP, Inc. Wettbewerber

BST:BPXA

€772.4k

XTRA:ECX

€1.3m

HMSE:SBH

€419.8k

DB:PA8K

€214.0k

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Forecast to breakeven in 2025

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Second quarter 2022 earnings released: US$0.013 loss per share (vs US$0.99 loss in 2Q 2021)

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.23 loss in 1Q 2021)

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings released: US$0.38 loss per share (vs US$1.11 loss in FY 2020)

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

Independent Chairman of the Board recently bought €212k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: €1.23

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

New 90-day high: €0.98

New 90-day low: €0.53

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

New 90-day low: €0.57

Third quarter 2020 earnings released: US$0.18 loss per share

Revenue beats expectations

PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®

PolarityTE, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €0.82

PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds

New 90-day low: €0.85

PolarityTE, Inc. Announces SkinTE™ Health Economics — DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure

New 90-day low - €0.94

First half earnings released

New 90-day high - €1.47

PolarityTE, Inc.(NasdaqCM:PTE) dropped from Russell Small Cap Completeness Index

Erträge & Einnahmen